Vaccination immunotherapy--an update.
Renal cell carcinoma is often regarded as an "immunogenic tumor". Organ-confined tumors are best treated by operative removal. Adjuvant strategies, however, may improve the outcome after operative therapy. Recently, a phase-III trial using an autologous renal tumor cell vaccine was able to demonstrate a reduction of the risk of progression in patients after radical nephrectomy for renal cell carcinoma larger than 2.5 cm. These results were achieved with minimal side effects. Patients with metastases have a poor prognosis. Thirty years ago autologous tumor cell vaccination resulted in remissions in a small number of patients. Almost all vaccination reports focus on patients with metastatic renal cell carcinoma. These reports differ considerably in their modes of preparation, stimulation, application route and intervals and other relevant parameters. More important, clinical response is limited in most studies. For metastatic renal cell carcinoma none of the various vaccination approaches are being currently investigated in phase-III trials. Ongoing efforts focus on development of more powerful vaccines. This review summarizes vaccination approaches for renal cell carcinomas published in the past 4 years.
Doehn
C
C
Department of Urology, University of Lübeck Medical School, Lübeck, Germany. doehn@medinf.mu-luebeck.de
Jocham
D
D
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D009362:Neoplasm Metastasis